查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球仿製药市场：按应用、类型、品牌、给药途径和分销管道划分的评估、机会和预测（2016-2030）
市场调查报告书
商品编码
1388970

全球仿製药市场：按应用、类型、品牌、给药途径和分销管道划分的评估、机会和预测（2016-2030）

Global Generic Drugs Market Assessment, By Application, By Type, By Brand, By Route of Administration, By Distribution Channel, By Region, Opportunities, and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 371 Pages | 商品交期: 3-5个工作天内

价格

预计2022年全球仿製药市场规模为3,356.5亿美元，2030年将达到5,827.6亿美元，在预测期（2023-2030年）成长7.06%，预计将以复合年增长率成长。 多种因素促进了全球仿製药市场的成长，包括慢性病患者数量的增加、老年人口的增加、技术进步、政府措施、医疗保健成本上升以及重磅药物的专利到期。

仿製药在已开发国家和发展中国家都越来越受欢迎，因为它们较便宜，且较少依赖跨国製药公司进行药物开发。 在获得专利持有人的许可后，复製这些药物所需的投资也较少。 随着一些品牌药物的专利到期，全球仿製药市场预计将迅速扩大。 旨在降低整体医疗保健成本和尽量减少慢性病盛行率的有利国家政策正在推动成长。 然而，严格的监管、品质问题和利润率下降等因素可能会阻碍全球仿製药市场的成长。

本报告分析了全球仿製药市场，提供了产品概述、市场基本结构、整体市场规模趋势展望、细分市场和地区详细趋势、市场背景和主要因素。我们正在调查影响因素、主要企业概况、市占率等。

目录

第一章研究方法

第 2 章专案范围与定义

第三章新型冠状病毒感染（COVID-19）的影响

第四章俄乌战争的影响

第 5 章执行摘要

第六章全球仿製药市场未来展望（2016-2030）

  • 市场规模与预测
    • 基于金额
    • 基于数量
  • 依用途
    • 神经血管（中枢神经系统）
    • 心血管
    • 皮肤科
    • 肿瘤
    • 糖尿病
    • 呼吸系统
    • 其他
  • 依类型
    • 生物相似药
    • 小分子仿製药
  • 按品牌
    • 品牌药学相似药
    • 纯通用
  • 依给药途径
    • 口腔医学
    • 注射药品
    • 外用药物
    • 其他
  • 按分销管道
    • 医院药房
    • 零售药局
    • 网路药局
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率（%，2022 年）

第七章全球仿製药市场未来展望：按地区划分（2016-2030）

  • 北美*
    • 依用途
    • 依类型
    • 按品牌
    • 依给药途径
    • 按分销管道
    • 美国*
      • 依用途
      • 依类型
      • 按品牌
      • 依给药途径
      • 按分销管道
    • 加拿大
    • 墨西哥

为涵盖的所有地区/国家提供每个细分市场的资讯。

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 西班牙
    • 波兰
    • 瑞士
    • 荷兰
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 泰国
    • 韩国
    • 新加坡
    • 马来西亚
    • 印尼
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非
    • 埃及
    • 阿尔及利亚
    • 以色列

第 8 章市场地图（2022 年）

  • 依用途
  • 依类型
  • 按品牌
  • 依给药途径
  • 按分销管道
  • 按地区

第九章宏观环境与产业结构

  • 需求与供给分析
  • 进出口分析（数量/价值基础）
  • 供应/价值链分析
  • PESTEL 分析
  • 波特五力分析

第 10 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 11 章市场动态

  • 生长促进因素
  • 抑製成长的因素（问题、限制）

第十二章主要公司状况

  • 前 5 名市场领导者：竞争矩阵
  • 前 5 位市场领导者：市场收入分析（%，2022 年）
  • 併购 (M&A)/合资企业（如果适用）
  • SWOT 分析（针对 5 家进入市场的公司）
  • 专利分析（如果适用）

第十三章价格分析

第 14 章个案研究

第15章主要公司展望

  • Viatris
    • 公司概况
    • 管理人员
    • 产品/服务
    • 财务状况（据报告）
    • 重点市场与地域分布
    • 近期趋势
  • Hikma Pharmaceuticals
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd.
  • Fresenius SE &Co. KGaA.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla
  • Aspen Holdings
  • Aurobindo Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Lupin
  • Others

上面列出的公司并非按市场份额排序，并且可能会根据研究工作中获得的资讯进行更改。

第16章战略建议

第 17 章关于 Market Xcel、免责声明

Product Code: MX10105

The Global Generic Drugs market size was estimated at USD 335.65 billion in 2022 and is projected to reach USD 582.76 billion in 2030, growing at a CAGR of 7.06% for the forecast period between 2023 and 2030F. Multiple factors contributing to the growth of the global generic drugs market are the increasing number of patients with chronic diseases, the rising geriatric population, technological advancements, government initiatives, rising healthcare costs, and expiring patents of blockbuster drugs.

Generic drugs are becoming increasingly popular in developed and developing countries because they are less expensive and reduce dependency on multinational pharmaceutical companies for developing drugs. It requires less investment to make copies of these drugs after obtaining the patent holder's permission. As the patents of several branded drugs expire, the global market for generic drugs will expand rapidly. Favorable policies in various nations that aim to lower overall healthcare costs and minimize the spread of chronic diseases are facilitating growth. However, factors such as stringent regulations, quality issues, and decreasing profit margins can hinder the growth of the global generic drugs market.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is having a substantial impact on the global generic drugs market. Chronic diseases such as cardiovascular, neurological, diabetes, and respiratory conditions are becoming increasingly common worldwide due to several factors, including changes in lifestyle, aging population, and environmental factors. According to National Institute of Health (NIH), the number of people 50 years of age and older who have at least one chronic condition is predicted to rise from 71.522 million (69.065-73.781) in 2020 to 142.66 million (134.74-153.39) in 2050, a 99.5% (95.1%-107.9%) increase. By 2060, a projected 48 million individuals (47% of all fatalities worldwide) are estimated to lose life due to serious health-related suffering, an 87% increase from 26 million in 2016. 83% of these casualties are expected to take place in low- and middle-income nations.

Growing Geriatric Population

The increase in the geriatric population is yet another factor that has significantly contributed to the rising demand for generic drugs. As people age, they often suffer from multiple health issues and chronic conditions, requiring long-term medication. Generic drugs, offer cost-effective alternatives to brand-name medications and become essential in managing these health concerns. Moreover, as patents for innovator or brand-name drugs expire, generic versions become available, providing affordable options without compromising on quality or efficacy. This accessibility to more affordable medications becomes crucial in addressing the healthcare needs of the aging population, thereby driving the demand for generic drugs.

One in six individuals on the planet will be 60 years of age or older by 2030. At this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of individuals in the world who are 60 years of age or older is expected to double (to 2.1 billion) by 2050. It is anticipated that between 2020 and 2050, the number of people 80 years of age or older will treble, reaching 426 million.

North America to Dominate the Market while Asia-Pacific is the Fastest Growing Region

North America is poised to dominate the global generic drugs market, with a market share of over 40% in 2022. This is mainly attributed to the high consumption of generic drugs and increasing prevalence of chronic diseases like cancer and diabetes in the region. Also, the region has an established framework for the approval process of generic medications and has global leaders in research and development activities. Asia-Pacific is expected to be the fastest-growing region in the Global Generic Drugs market due to the increasing adoption of generic drugs in the healthcare system to reduce healthcare spending. Governments in countries like China, India, and Japan are heavily promoting the use of generic drugs through incentivization and substitute programs. Additionally, the region's focus on better quality generics and supportive policies and investments position Asia-Pacific as a key market player in the global generic drugs market.

United States is the leading region within the North America generic drugs market. This leading position is driven by factors such as patent expirations, a streamlined FDA approval process, and a regulatory environment that fosters competition. The availability of generic alternatives after patent expirations contributes to cost containment in healthcare in the region, as generic drugs offer more affordable options. The United States market continues to prioritize the adoption of generic drugs to address rising healthcare costs while maintaining therapeutic effectiveness. As per the United States Generic & Biosimilar Medicines Savings Report 2023, generic drugs takes 90% of all the prescription in the United States but represents only 17.5% of total prescription drug spending and less than 2% of all healthcare spending.

Cardiovascular Drugs Contribute to Major Market Share

Cardiovascular drugs dominated the global generic drugs market with around one-third of the total market share in 2022. The growth is mainly attributed to the increasing prevalence of cardiovascular diseases across the globe due to sedentary lifestyle and unhealthy food habits. As per World Health Organization (WHO), cardiovascular diseases are the major cause of the global mortality rate marking nearly 17.9 million deaths per year worldwide. Heart attacks and strokes account for over 80% of cardiovascular deaths, with about a third of these fatalities happening prematurely among individuals below the age of 70 years. An unhealthy diet, low physical inactivity, consumption of tobacco, and excessive alcohol consumption are the primary behavioral factors that significantly contribute to heart diseases and stroke. These behaviors can lead to high blood pressure, increased blood glucose levels, elevated blood lipids, as well as overweight and obesity in individuals. According to a recent World Health Organization (WHO) report, non-communicable diseases, or NCDs like cardiovascular diseases, account for over three-quarters of all fatalities worldwide.

Biosimilar Generics to Dominate the Market

The biosimilar generics segment held the dominant market share in the global generics drug market in 2022 and is expected to maintain its dominance over the forecast period. Biosimilars are generic versions of biologics, but at much more affordable prices, making them a dominant segment across the market. Several other factors also contribute to the expected dominance of biosimilar generics, like the patent expiration of many blockbuster biologic drugs, opening opportunities for biosimilar manufacturers to enter the market with more affordable versions.

Moreover, biosimilars offer an alternative way to reduce the rising healthcare costs for patients and healthcare systems without compromising quality. Due to these factors and the ongoing need for cost-effective alternatives, the biosimilar generics segment is poised to maintain its dominance in the global generics drug market, especially in addressing the healthcare needs of aging populations and chronic disease management.

For instance, according to United States Generic & Biosimilar Medicines Savings Report 2023, the use of biosimilar generics is on the rise which compels the innovators to reduce the cost of biologics, thus saving USD 9.4 billion in the year 2022 alone.

Oral Drugs Being the Most Preferred Route of Administration

The oral generic drug segment dominated the global generic drugs market, holding nearly two-thirds of the market share in 2022 globally. Among the different methods of drug delivery, oral administration is preferred over injectables due to its numerous advantages. These benefits encompass safety, high patient adherence, easy ingestion, avoidance of pain, and the ability to accommodate a wide range of medications, making it a versatile option. Hetero, a pharmaceutical company based in Hyderabad, India, declared in 2022 that its generic form of the COVID-19 oral antiviral treatment candidate nirmatrelvir had obtained approval from the World Health Organization Prequalification of Medicines Program (WHO PQ).

Retail Pharmacy to Dominate the Market

Retail pharmacy will dominate the global generic drugs market over the forecast period. Retail pharmacies serve as pivotal nodes within the distribution network and act as accessible hubs for patients to acquire generic medications. Their ubiquitous presence fosters convenience and facilitates widespread access to affordable generic drugs. Leveraging this convenience, retail pharmacies establish a direct link between consumers and a diverse range of generic medications, catering to a spectrum of medical needs. Moreover, the increasing demand for cost-effective healthcare solutions propels the significance of generic drugs, and retail pharmacies stand as the primary gateway for consumers to procure these affordable alternatives to brand-name medications.

Technological Advancements

With the advent of RPA (Robotic Process Automation) and AI in the pharmaceutical industry, automation has helped in overcoming difficulties and improving efficiency. RPA and AI aid in increasing productivity, lowering costs, and improving performance. Through automation, these technologies also assure regulatory compliance within an organization's process. Artificial intelligence, machine learning and natural language processing are being used extensively in research and development of pharmaceutical drugs. Predictive analytics and natural language processing are used to scan databases of brand name medicine compounds for similar compounds that scientists can use to develop generic drugs. Machine learning is used to determine a compound's solubility in order to ensure that it retains its effectiveness over time.

Government Initiatives

Developed countries' governments are trying to reduce healthcare costs by promoting the manufacturing of generic drugs. On the other hand, healthcare industries in developing countries are affected by issues like affordability and accessibility. In the United States, the Food and Drug Administration (FDA) has taken various steps to expedite the approval process for generic drugs, including the Generic Drug User Fee Amendments (GDUFA) program, which aims to speed up the review of generic drug applications. In the European Union, the European Medicines Agency (EMA) has also implemented initiatives to streamline the approval process for generic drugs, such as the generic medicines work-sharing initiative, which allows regulators from different countries to work together to assess the safety and efficacy of generic medicines. Overall, these initiatives by governments around the world are helping to increase the availability and affordability of generic drugs, thereby improving access to healthcare for patients. To promote the use of generic drugs, the Indian government established more than 9,000 Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJK) till 2022. These centers sell generic drugs at much lower rates with the help of government subsidies.

Impact of COVID-19

The COVID-19 pandemic had a short-term and long-term impact on the pharmaceutical sector. Short term impacts such as demand change, panic buying, supply shortage of API (active pharmaceutical ingredient) and finished products. Long-term impacts include delayed approvals for non-COVID-related pharmaceutical products, ethical considerations, and consumption trend changes in health-related products. Supply chain was a major factor impacting the generic drugs market. Many countries rely on India and China to produce generic drugs, and the pandemic led to disruptions in the production and distribution of drugs due to factory closures and supply chain disruptions.

The pandemic also increased demand for certain generic drugs, particularly those used to treat COVID-19 symptoms such as fever and respiratory distress, which led to shortages of these drugs in some regions and price hikes. Furthermore, the pandemic has also highlighted the importance of investing in research and development for new generic drugs, particularly for COVID-19 treatments and vaccines.

Impact of Russia-Ukraine War

Russia's invasion of Ukraine affected millions of people, not just in Eastern Europe nations but throughout the world. Drug developers experienced development delays, lost business continuity, and the threat of noncompliance for on-market drugs. Drugmakers such as Novartis, AbbVie, Eli Lilly and hundreds of companies announced a pause or withdrawal of business in Russia. The Director General of Pharmexcil (Pharmaceutical Export Promotion Council of India) expressed concerns about Indian pharmaceutical exports losing ground in the CIS (Commonwealth of Independent States). He also expressed that India might lose a few millions in terms of exports to CIS and Russia, since Russia is one of the top five exporting destinations of India and Ukraine is the third largest exporter of pharmaceuticals for India. Indian drug companies such as Dr Reddy's Laboratories and Sun Pharma have strong presence in Ukraine and Russia.

Key Players Landscape and Outlook

The Global Generic Drugs market is dominated by Viatris, Fresenius SE & Co. KGaA., Novartis AG, Teva Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Cipla, Dr. Reddy's Laboratories, Lupin and many others.

In March 2023, MPP (Medicines Patent Pool), a United Nations-supported public health organisation, announced that it has entered into sublicensing agreements with three drug companies-Aurobindo Pharma, Cipla, and Viatris- for the manufacturing of generic variants of ViiV Healthcare's long-acting HIV prevention medicine. According to the agreement, the organizations would produce the generic version of the medication in India, with Cipla also planning to produce the drug in South Africa.

In May 2023, Teva Pharmaceutical Industries Ltd. revealed a fresh strategic framework encompassing four primary pillars intended to reposition the Company for a forthcoming phase of expansion. The strategy is designed to fortify the Company's robust commercial portfolio, featuring AUSTEDO, AJOVY, UZEDYTM, and biosimilars, while simultaneously amplifying its innovative pipeline. Additionally, it aims to maintain the Company's dominance in the generics sector and concentrate on streamlining its business operations.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Global Generic Drugs Market Outlook, 2016-2030F

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
    • 6.1.2. By Volume
  • 6.2. By Application
    • 6.2.1. Neurovascular (Central Nervous System)
    • 6.2.2. Cardiovascular
    • 6.2.3. Dermatology
    • 6.2.4. Oncology
    • 6.2.5. Diabetology
    • 6.2.6. Respiratory
    • 6.2.7. Others
  • 6.3. By Type
    • 6.3.1. Biosimilar Generics
    • 6.3.2. Small Molecule Generics
  • 6.4. By Brand
    • 6.4.1. Branded Generic
    • 6.4.2. Pure Generic
  • 6.5. By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Injectable
    • 6.5.3. Topical
    • 6.5.4. Others
  • 6.6. By Distribution Channel
    • 6.6.1. Hospital Pharmacy
    • 6.6.2. Retail Pharmacy
    • 6.6.3. Online Pharmacy
  • 6.7. By Region
    • 6.7.1. North America
    • 6.7.2. Europe
    • 6.7.3. Asia Pacific
    • 6.7.4. South America
    • 6.7.5. Middle East and Africa
  • 6.8. By Company Market Share (%), 2022

7. Global Generic Drugs Market Outlook, By Region, 2016-2030F

  • 7.1. North America*
    • 7.1.1. By Application
      • 7.1.1.1. Neurovascular (Central Nervous System)
      • 7.1.1.2. Cardiovascular
      • 7.1.1.3. Dermatology
      • 7.1.1.4. Oncology
      • 7.1.1.5. Diabetology
      • 7.1.1.6. Respiratory
      • 7.1.1.7. Others
    • 7.1.2. By Type
      • 7.1.2.1. Biosimilar Generics
      • 7.1.2.2. Small Molecule Generics
    • 7.1.3. By Brand
      • 7.1.3.1. Branded Generic
      • 7.1.3.2. Pure Generic
    • 7.1.4. By Route of Administration
      • 7.1.4.1. Oral
      • 7.1.4.2. Injectable
      • 7.1.4.3. Topical
      • 7.1.4.4. Others
    • 7.1.5. By Distribution Channel
      • 7.1.5.1. Hospital Pharmacy
      • 7.1.5.2. Retail Pharmacy
      • 7.1.5.3. Online Pharmacy
    • 7.1.6. United States*
      • 7.1.6.1. By Application
      • 7.1.6.1.1. Neurovascular (Central Nervous System)
      • 7.1.6.1.2. Cardiovascular
      • 7.1.6.1.3. Dermatology
      • 7.1.6.1.4. Oncology
      • 7.1.6.1.5. Diabetology
      • 7.1.6.1.6. Respiratory
      • 7.1.6.1.7. Others
      • 7.1.6.2. By Type
      • 7.1.6.2.1. Biosimilar Generics
      • 7.1.6.2.2. Small Molecule Generics
      • 7.1.6.3. By Brand
      • 7.1.6.3.1. Branded Generic
      • 7.1.6.3.2. Pure Generic
      • 7.1.6.4. By Route of Administration
      • 7.1.6.4.1. Oral
      • 7.1.6.4.2. Injectable
      • 7.1.6.4.3. Topical
      • 7.1.6.4.4. Others
      • 7.1.6.5. By Distribution Channel
      • 7.1.6.5.1. Hospital Pharmacy
      • 7.1.6.5.2. Retail Pharmacy
      • 7.1.6.5.3. Online Pharmacy
    • 7.1.7. Canada
    • 7.1.8. Mexico

All segments will be provided for all regions and countries covered:

  • 7.1 Europe
    • 7.1.1 Germany
    • 7.1.2 France
    • 7.1.3 Italy
    • 7.1.4 United Kingdom
    • 7.1.5 Spain
    • 7.1.6 Poland
    • 7.1.7 Switzerland
    • 7.1.8 Netherlands
  • 7.2 South America
    • 7.2.1 Brazil
    • 7.2.2 Argentina
    • 7.2.3 Colombia
    • 7.2.4 Chile
  • 7.3 Asia-Pacific
    • 7.3.1 India
    • 7.3.2 China
    • 7.3.3 Japan
    • 7.3.4 Australia
    • 7.3.5 Thailand
    • 7.3.6 South Korea
    • 7.3.7 Singapore
    • 7.3.8 Malaysia
    • 7.3.9 Indonesia
    • 7.3.10 Philippines
  • 7.4 Middle East & Africa
    • 7.4.1 Saudi Arabia
    • 7.4.2 UAE
    • 7.4.3 South Africa
    • 7.4.4 Egypt
    • 7.4.5 Algeria
    • 7.4.6 Israel

8. Market Mapping, 2022

  • 8.1. By Application
  • 8.2. By Type
  • 8.3. By Brand
  • 8.4. By Route of Administration
  • 8.5. By Distribution Channel
  • 8.6. By Region

9. Macro Environment and Industry Structure

  • 9.1. Supply Demand Analysis
  • 9.2. Import Export Analysis - Volume and Value
  • 9.3. Supply/Value Chain Analysis
  • 9.4. PESTEL Analysis
    • 9.4.1. Political Factors
    • 9.4.2. Economic System
    • 9.4.3. Social Implications
    • 9.4.4. Technological Advancements
    • 9.4.5. Environmental Impacts
    • 9.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 9.5. Porter's Five Forces Analysis
    • 9.5.1. Supplier Power
    • 9.5.2. Buyer Power
    • 9.5.3. Substitution Threat
    • 9.5.4. Threat from New Entrant
    • 9.5.5. Competitive Rivalry

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Market Dynamics

  • 11.1. Growth Drivers
  • 11.2. Growth Inhibitors (Challenges, Restraints)

12. Key Players Landscape

  • 12.1. Competition Matrix of Top Five Market Leaders
  • 12.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 12.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 12.4. SWOT Analysis (For Five Market Players)
  • 12.5. Patent Analysis (If Applicable)

13. Pricing Analysis

14. Case Studies

15. Key Players Outlook

  • 15.1. Viatris
    • 15.1.1. Company Details
    • 15.1.2. Key Management Personnel
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As reported)
    • 15.1.5. Key Market Focus & Geographical Presence
    • 15.1.6. Recent Developments
  • 15.2. Hikma Pharmaceuticals
  • 15.3. Novartis AG
  • 15.4. Teva Pharmaceuticals Industries Ltd.
  • 15.5. Fresenius SE & Co. KGaA.
  • 15.6. Sun Pharmaceutical Industries Ltd.
  • 15.7. Cipla
  • 15.8. Aspen Holdings
  • 15.9. Aurobindo Pharmaceuticals
  • 15.10. Dr. Reddy's Laboratories
  • 15.11. Lupin
  • 15.12. Others

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 3. Global Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 4. Global Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 5. Global Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 6. Global Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 7. Global Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 8. Global Generic Drugs Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 9. North America Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 10. North America Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 11. North America Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 12. North America Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 13. North America Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 14. North America Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 15. North America Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 16. North America Generic Drugs Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 17. United States Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 18. United States Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 19. United States Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 20. United States Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 21. United States Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 22. United States Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 23. United States Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 24. Canada Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 25. Canada Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 26. Canada Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 27. Canada Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 28. Canada Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 29. Canada Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 30. Canada Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 31. Mexico Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 32. Mexico Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 33. Mexico Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 34. Mexico Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 35. Mexico Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 36. Mexico Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 37. Mexico Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 38. Europe Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 39. Europe Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 40. Europe Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 41. Europe Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 42. Europe Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 43. Europe Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 44. Europe Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 45. Europe Generic Drugs Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 46. Germany Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. Germany Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 48. Germany Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 49. Germany Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 50. Germany Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 51. Germany Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 52. Germany Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 53. France Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 54. France Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 55. France Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 56. France Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 57. France Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 58. France Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 59. France Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 60. Italy Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 61. Italy Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 62. Italy Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 63. Italy Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 64. Italy Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 65. Italy Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 66. Italy Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 67. United Kingdom Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 68. United Kingdom Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 69. United Kingdom Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 70. United Kingdom Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 71. United Kingdom Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 72. United Kingdom Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 73. United Kingdom Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 74. Spain Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 75. Spain Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 76. Spain Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 77. Spain Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 78. Spain Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 79. Spain Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 80. Spain Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 81. Poland Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 82. Poland Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 83. Poland Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 84. Poland Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 85. Poland Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 86. Poland Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 87. Poland Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 88. Switzerland Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Switzerland Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 90. Switzerland Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 91. Switzerland Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 92. Switzerland Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 93. Switzerland Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 94. Switzerland Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 95. Netherlands Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 96. Netherlands Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 97. Netherlands Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 98. Netherlands Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 99. Netherlands Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 100. Netherlands Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 101. Netherlands Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 102. South America Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 103. South America Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 104. South America Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 105. South America Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 106. South America Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 107. South America Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 108. South America Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 109. South America Generic Drugs Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 110. Brazil Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 111. Brazil Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 112. Brazil Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 113. Brazil Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 114. Brazil Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 115. Brazil Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 116. Brazil Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 117. Argentina Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 118. Argentina Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 119. Argentina Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 120. Argentina Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 121. Argentina Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 122. Argentina Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 123. Argentina Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 124. Colombia Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 125. Colombia Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 126. Colombia Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 127. Colombia Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 128. Colombia Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 129. Colombia Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 130. Colombia Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 131. Chile Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 132. Chile Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 133. Chile Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 134. Chile Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 135. Chile Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 136. Chile Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 137. Chile Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 138. Asia-Pacific Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 139. Asia-Pacific Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 140. Asia-Pacific Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 141. Asia-Pacific Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 142. Asia-Pacific Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 143. Asia-Pacific Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 144. Asia- Pacific Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 145. Asia-Pacific Generic Drugs Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 146. India Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 147. India Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 148. India Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 149. India Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 150. India Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 151. India Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 152. India Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 153. China Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 154. China Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 155. China Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 156. China Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 157. China Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 158. China Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 159. China Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 160. Japan Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 161. Japan Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 162. Japan Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 163. Japan Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 164. Japan Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 165. Japan Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 166. Japan Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 167. Australia Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 168. Australia Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 169. Australia Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 170. Australia Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 171. Australia Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 172. Australia Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 173. Australia Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 174. Thailand Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 175. Thailand Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 176. Thailand Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 177. Thailand Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 178. Thailand Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 179. Thailand Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 180. Thailand Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 181. South Korea Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. South Korea Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 183. South Korea Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 184. South Korea Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 185. South Korea Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 186. South Korea Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 187. South Korea Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 188. Singapore Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 189. Singapore Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 190. Singapore Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 191. Singapore Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 192. Singapore Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 193. Singapore Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 194. Singapore Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 195. Malaysia Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 196. Malaysia Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 197. Malaysia Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 198. Malaysia Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 199. Malaysia Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 200. Malaysia Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 201. Malaysia Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 202. Indonesia Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 203. Indonesia Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 204. Indonesia Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 205. Indonesia Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 206. Indonesia Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 207. Indonesia Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 208. Indonesia Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 209. Philippines Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 210. Philippines Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 211. Philippines Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 212. Philippines Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 213. Philippines Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 214. Philippines Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 215. Philippines Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 216. Middle East & Africa Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 217. Middle East & Africa Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 218. Middle East & Africa Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 219. Middle East & Africa Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 220. Middle East & Africa Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 221. Middle East & Africa Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 222. Middle East & Africa Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 223. Middle East & Africa Generic Drugs Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 224. Saudi Arabia Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 225. Saudi Arabia Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 226. Saudi Arabia Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 227. Saudi Arabia Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 228. Saudi Arabia Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 229. Saudi Arabia Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 230. Saudi Arabia Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 231. UAE Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 232. UAE Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 233. UAE Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 234. UAE Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 235. UAE Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 236. UAE Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 237. UAE Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 238. South Africa Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 239. South Africa Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 240. South Africa Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 241. South Africa Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 242. South Africa Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 243. South Africa Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 244. South Africa Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 245. Egypt Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 246. Egypt Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 247. Egypt Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 248. Egypt Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 249. Egypt Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 250. Egypt Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 251. Egypt Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 252. Algeria Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 253. Algeria Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 254. Algeria Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 255. Algeria Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 256. Algeria Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 257. Algeria Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 258. Algeria Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 259. Israel Generic Drugs Market, By Value, In USD Billion, 2016-2030F
  • Figure 260. Israel Generic Drugs Market, By Volume, In Million Prescriptions, 2016-2030F
  • Figure 261. Israel Generic Drugs Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 262. Israel Generic Drugs Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 263. Israel Generic Drugs Market Share, By Brand, In USD Billion, 2016-2030F
  • Figure 264. Israel Generic Drugs Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 265. Israel Generic Drugs Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 266. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 267. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 268. By Brand Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 269. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 270. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 271. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022